ACLARIS THERAPEUTICS INC (ACRS) Stock Earnings & Estimates
NASDAQ:ACRS - US00461U1051 - Common Stock
2.13 USD
+0.05 (+2.65%)
2.1696 USD
+0.04 (+1.86%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 29.75M 340.09% | 31.249M 5.04% | 18.72M -40.09% | 5.709M -69.50% | 5.612M -1.70% | 6.377M 13.63% | 11.038M 73.09% | 36.844M 233.79% | 92.577M 151.27% | 119M 28.54% | 268.29M 125.45% | |
| EBITDA YoY % growth | -84.35M -30.86% | -88.551M -4.98% | -51.52M 41.82% | -78.452M -52.28% | -83.36M -6.26% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -85.15M -30.24% | -89.414M -5.01% | -52.327M 41.48% | -72.773M -39.07% | -80.543M -10.68% | -106.294M -31.97% | -101.09M 4.90% | -119.362M -18.07% | -152.316M -27.61% | -75.378M 50.51% | 48.484M 164.32% | |
| Operating Margin | -286.22% | -286.13% | -279.52% | -1,274.70% | -1,435.19% | -1,666.83% | -915.84% | -323.97% | -164.53% | -63.34% | 18.07% | |
| EPS YoY % growth | -1.33 18.40% | -1.25 6.02% | -1.51 -20.80% | -0.53 65.21% | -0.54 -3.56% | -0.65 -19.81% | -0.89 -36.93% | -0.73 18.29% | 0.01 100.70% | 0.33 6,300.00% | 1.03 215.63% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.13 -19.22% | -0.14 86.29% | -0.14 -13.33% | -0.14 -7.23% | -0.13 -1.11% | -0.13 7.89% | -0.13 4.75% | -0.10 25.37% | -0.07 46.15% | -0.07 48.80% |
| Revenue Q2Q % growth | 1.621M -62.70% | 1.606M -82.56% | 1.428M -1.86% | 1.428M -19.64% | 1.428M -11.91% | 1.428M -11.08% | 1.813M 26.96% | 1.813M 26.96% | 1.813M 26.96% | 1.813M 26.96% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -17.319M -65.40% | -18.345M -43.66% | -17.136M 5.24% | -17.442M 5.25% | -17.85M -3.07% | -18.156M 1.03% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.13 13.33% | -0.14 | 0.01 | 4.07% |
| Q1 2025 Q2Q % growth | -0.12 50.00% | -0.12 | 0.00 | -0.13% |
| Q4 2024 Q2Q % growth | -1.01 -4,950.00% | -0.22 | -0.79 | -353.03% |
| Q3 2024 Q2Q % growth | -0.11 73.17% | -0.01 | -0.10 | -1,788.67% |
| Q2 2024 Q2Q % growth | -0.15 64.29% | -0.21 | 0.06 | 28.07% |
| Q1 2024 Q2Q % growth | -0.24 40.00% | -0.29 | 0.05 | 17.65% |
| Q4 2023 Q2Q % growth | -0.02 95.12% | -0.35 | 0.33 | 94.31% |
| Q3 2023 Q2Q % growth | -0.41 -36.67% | -0.49 | 0.08 | 16.26% |
| Q2 2023 Q2Q % growth | -0.42 -35.48% | -0.46 | 0.04 | 8.50% |
| Q1 2023 Q2Q % growth | -0.40 -29.03% | -0.45 | 0.05 | 10.42% |
| Q4 2022 Q2Q % growth | -0.41 -10.81% | -0.45 | 0.04 | 9.79% |
| Q3 2022 Q2Q % growth | -0.30 14.29% | -0.40 | 0.10 | 25.67% |
| Q2 2022 Q2Q % growth | -0.31 8.82% | -0.37 | 0.06 | 15.18% |
| Q1 2022 Q2Q % growth | -0.31 45.61% | -0.41 | 0.10 | 24.65% |
| Q4 2021 Q2Q % growth | -0.37 -23.33% | -0.37 | 0.00 | 0.62% |
| Q3 2021 Q2Q % growth | -0.35 -40.00% | -0.29 | -0.06 | -22.55% |
| Q2 2021 Q2Q % growth | -0.34 -21.43% | -0.28 | -0.06 | -20.48% |
| Q1 2021 Q2Q % growth | -0.57 -54.05% | -0.29 | -0.28 | -94.37% |
| Q4 2020 Q2Q % growth | -0.30 33.33% | -0.27 | -0.03 | -10.29% |
| Q3 2020 Q2Q % growth | -0.25 81.34% | -0.31 | 0.06 | 19.20% |
| Q2 2020 Q2Q % growth | -0.28 63.16% | -0.37 | 0.09 | 23.75% |
| Q1 2020 Q2Q % growth | -0.37 59.34% | -0.33 | -0.04 | -11.61% |
| Q4 2019 Q2Q % growth | -0.45 | -0.40 | -0.05 | -11.69% |
| Q3 2019 Q2Q % growth | -1.34 | -0.58 | -0.76 | -131.83% |
| Q2 2019 Q2Q % growth | -0.76 | -0.77 | 0.01 | 1.64% |
| Q1 2019 Q2Q % growth | -0.91 | -0.82 | -0.09 | -11.17% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.777M -35.76% | 1.4M | 377K | 26.93% |
| Q1 2025 Q2Q % growth | 1.455M -39.32% | 1.306M | 149K | 11.41% |
| Q4 2024 Q2Q % growth | 9.211M -47.58% | 2.15M | 7.061M | 328.42% |
| Q3 2024 Q2Q % growth | 4.346M -53.18% | 7.262M | -2.916M | -40.15% |
| Q2 2024 Q2Q % growth | 2.766M 47.99% | 1.854M | 912K | 49.19% |
| Q1 2024 Q2Q % growth | 2.398M -5.14% | 1.394M | 1.004M | 72.02% |
| Q4 2023 Q2Q % growth | 17.57M 126.71% | 3.431M | 14.139M | 412.10% |
| Q3 2023 Q2Q % growth | 9.282M -51.20% | 1.605M | 7.677M | 478.32% |
| Q2 2023 Q2Q % growth | 1.869M 22.16% | 1.937M | -68K | -3.51% |
| Q1 2023 Q2Q % growth | 2.528M 74.34% | 1.783M | 745K | 41.78% |
| Q4 2022 Q2Q % growth | 7.75M 416.67% | 2.034M | 5.716M | 281.02% |
| Q3 2022 Q2Q % growth | 19.02M 1,045.78% | 1.637M | 17.383M | 1,061.88% |
| Q2 2022 Q2Q % growth | 1.53M -15.93% | 1.644M | -114K | -6.93% |
| Q1 2022 Q2Q % growth | 1.45M -18.54% | 1.698M | -248K | -14.61% |
| Q4 2021 Q2Q % growth | 1.5M -5.06% | 1.827M | -327K | -17.90% |
| Q3 2021 Q2Q % growth | 1.66M 14.48% | 1.806M | -146K | -8.08% |
| Q2 2021 Q2Q % growth | 1.82M -11.22% | 1.781M | 39K | 2.19% |
| Q1 2021 Q2Q % growth | 1.78M 26.24% | 1.512M | 268K | 17.72% |
| Q4 2020 Q2Q % growth | 1.58M 43.64% | 1.418M | 162K | 11.42% |
| Q3 2020 Q2Q % growth | 1.45M 47.96% | 1.499M | -49K | -3.27% |
| Q2 2020 Q2Q % growth | 2.05M 130.34% | 1.259M | 791K | 62.83% |
| Q1 2020 Q2Q % growth | 1.41M 11.90% | 1.152M | 258K | 22.40% |
| Q4 2019 Q2Q % growth | 1.1M | 3.23M | -2.13M | -65.94% |
| Q3 2019 Q2Q % growth | 980K | 5.939M | -4.959M | -83.50% |
| Q2 2019 Q2Q % growth | 890K | 5.657M | -4.767M | -84.27% |
| Q1 2019 Q2Q % growth | 1.26M | 4.909M | -3.649M | -74.33% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 8.16% | 14.29% | 5.38% | 8.44% |
| Revenue | 9.9% | 1.69% | -2.97% | -6.5% |